US FDA Approves Adapt Pharma’s Nasal Spray for Opioid Overdose

Published By : 20 Nov 2015 | Published By : QYRESEARCH

In a recent development concerning the treatment of overdose of opioid, the U.S. Food and Drug Administration (US FDA) has approved an easy to use nasal spray. The spray, titled Narcan, a version of naloxone hydrochloride, is developed by the company Adapt Pharma and is one of its kinds to have earned the approval of the regulatory body. The nasal spray is being considered a life saving medication that can stop or reverse the effects caused by the overdose of opioids.

It is expected that the spray will be available in the market early next year. It is an investigational medication designed especially for providing a dose of naloxone in the form of nasal spray.

The medication is indicated for emergency treatment of a known or a suspected case of opioid overdose, as marked by central nervous system or respiratory system depression.

The spray is intended for use in emergency situations in settings where opioid may exist. The spray is inadvisable for patients who are known to be hypersensitive to the use of naloxone hydrochloride.

About the approval of the medication by the U.S. FDA, the chairman and CEO of Adapt Pharma, Seamus Mulligan, said that the needle free, ready to use Narcan Nasal Spray delivers a dose of 4 mg of naloxone in a single spray of 0.1 ml volume capacity.

The new device will make naloxone easily and readily available for use in emergency situations and can be used by a friend, caregiver, and family members. It also offers an alternative treatment option for healthcare providers and first responders to a case of opioid overdose.
The Centers for Disease Control and Prevention states that opioid overdose has resulted in over 24,500 deaths in the U.S. in 2013, a four times high number than 1999.

Back To Top